MA56550A - Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation - Google Patents
Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparationInfo
- Publication number
- MA56550A MA56550A MA056550A MA56550A MA56550A MA 56550 A MA56550 A MA 56550A MA 056550 A MA056550 A MA 056550A MA 56550 A MA56550 A MA 56550A MA 56550 A MA56550 A MA 56550A
- Authority
- MA
- Morocco
- Prior art keywords
- diazaspiro
- octane
- carboxylate
- oxo
- tert
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865826P | 2019-06-24 | 2019-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56550A true MA56550A (fr) | 2022-04-27 |
Family
ID=74060350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056550A MA56550A (fr) | 2019-06-24 | 2020-06-23 | Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220267341A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986399A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7617043B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260061467A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364380A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304001B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026380A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144600A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289198A (cg-RX-API-DMAC7.html) |
| MA (1) | MA56550A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000069A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020263847A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| JP6419087B2 (ja) * | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
| CA2898861C (en) * | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| TWI738748B (zh) * | 2016-03-28 | 2021-09-11 | 日商武田藥品工業有限公司 | 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形 |
| PE20190174A1 (es) * | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| TWI887245B (zh) * | 2019-06-24 | 2025-06-21 | 美商諾雷克斯股份有限公司 | 用於產生二氮雜螺內醯胺化合物之方法及中間物 |
-
2020
- 2020-06-23 BR BR112021026380A patent/BR112021026380A2/pt unknown
- 2020-06-23 EP EP20832010.1A patent/EP3986399A4/en active Pending
- 2020-06-23 JP JP2021576883A patent/JP7617043B2/ja active Active
- 2020-06-23 MA MA056550A patent/MA56550A/fr unknown
- 2020-06-23 US US17/621,907 patent/US20220267341A1/en active Pending
- 2020-06-23 KR KR1020267012575A patent/KR20260061467A/ko active Pending
- 2020-06-23 CN CN202080059974.0A patent/CN114364380A/zh active Pending
- 2020-06-23 MX MX2022000069A patent/MX2022000069A/es unknown
- 2020-06-23 WO PCT/US2020/039163 patent/WO2020263847A1/en not_active Ceased
- 2020-06-23 AU AU2020304001A patent/AU2020304001B2/en active Active
- 2020-06-23 KR KR1020227002351A patent/KR102958083B1/ko active Active
- 2020-06-23 CA CA3144600A patent/CA3144600A1/en active Pending
-
2021
- 2021-12-21 IL IL289198A patent/IL289198A/en unknown
-
2022
- 2022-01-03 MX MX2025002579A patent/MX2025002579A/es unknown
-
2025
- 2025-01-06 JP JP2025001914A patent/JP7858096B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114364380A (zh) | 2022-04-15 |
| JP2022539342A (ja) | 2022-09-08 |
| WO2020263847A1 (en) | 2020-12-30 |
| MX2025002579A (es) | 2025-04-02 |
| US20220267341A1 (en) | 2022-08-25 |
| EP3986399A4 (en) | 2023-06-07 |
| AU2020304001A1 (en) | 2022-01-27 |
| EP3986399A1 (en) | 2022-04-27 |
| JP7617043B2 (ja) | 2025-01-17 |
| CA3144600A1 (en) | 2020-12-30 |
| AU2020304001B2 (en) | 2026-04-09 |
| IL289198A (en) | 2022-02-01 |
| MX2022000069A (es) | 2022-05-24 |
| KR20260061467A (ko) | 2026-05-06 |
| KR20220061088A (ko) | 2022-05-12 |
| JP7858096B2 (ja) | 2026-05-13 |
| BR112021026380A2 (pt) | 2022-05-10 |
| JP2025069143A (ja) | 2025-04-30 |
| KR102958083B1 (ko) | 2026-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285782A (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3980046A4 (en) | KRAS G12V MUTANT THAT BINDS TO JAK1, INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | |
| EP3893655A4 (en) | METHOD OF PREPARING A PLANT PROTEIN COMPOSITION | |
| EP3978029A4 (en) | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF MANUFACTURE AND USE | |
| EP3914651A4 (en) | CARBONATE AGGREGATE COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION AND USE | |
| MX2020009290A (es) | Inhibidores de la arginasa. | |
| WO2007027527A3 (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| EP3359159A4 (en) | PHARMACEUTICAL SALTS, PHYSICAL FORMS AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP4585270A3 (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
| EP3773900A4 (en) | HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| EP3606929A4 (en) | BETA NICOTINATE ESTERNUCLEOTIDES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3969457A4 (en) | PROCESS FOR THE PRODUCTION OF MACROCYCLIC INDOLES | |
| MA53427B1 (fr) | Inhibiteurs de l'arginase et leurs méthodes d'utilisation | |
| EP3325456A4 (en) | CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2,2-DIPHENYL-3-FURANOMETHANAMINE HYDROCHLORIDE, METHOD FOR THE PREPARATION OF SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| MA56132A (fr) | Procédés de purification d'anticorps et compositions associées | |
| EP4286381A3 (en) | Treatment of merkel celll carcinoma | |
| EP3986399A4 (en) | SOLID FORMS OF TERT-BUTYL (S)-2-((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO-2,5-DIAZASPIRO[3.4]OCTANE E-5-CARBOXYLATE AND PROCESS OF PRODUCTION | |
| WO2017095950A3 (en) | Compounds for treating proliferative diseases | |
| MA50862A (fr) | Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30 | |
| EP3411359A4 (en) | PROCESS FOR PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF INFECTION PROTECTION AGENTS | |
| EP4031130A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS | |
| EP3921322A4 (en) | PHOSPHORUS-IMIDAZOCHINOLINE-AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF |